Number of shares and voting rights of Innate Pharma as of April 25, 2025
Innate Pharma announces €15m investment by Sanofi
Innate Pharma regains its rights on CD123 targeting ANKET® and announces Sanofi’s intention to make a strategic investment in the Company
Innate Pharma proposes to its shareholders to transform its corporate governance structure into a board of directors and to change its composition
Innate Pharma to hold its Annual General Meeting of shareholders on May 22, 2025
Innate Pharma to participate in the 2025 Stifel Virtual Targeted Oncology Forum
Innate Pharma reports full year 2024 financial results and business update
Innate Pharma highlights antibody drug conjugate IPH4502 abstract selected for the AACR 2025 annual meeting
Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference
Innate Pharma announces conference call and webcast for full year 2024 financial results
